



Vaccines and Global Health: The Week in Review
03 August 2024 :: Issue 762
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

Milestones, Perspectives

.....
.....

Polio – PHEIC

Children in Gaza are now at risk of polio as well as bombs – we need a ceasefire now

Tedros Adhanom Ghebreyesus, DG, WHO

Opinion The Guardian 26 Jul 2024

We are sending 1m polio vaccines to Gaza but many people will die from preventable health threats unless we can quickly scale up aid delivery, says the WHO director general

The polio virus was detected in wastewater samples in Gaza last week, an alarming yet unsurprising development given the dismantled state of the territory's health systems after nine relentless months of war.

Across Gaza, more than 39 000 people have been killed, 89 000 wounded, and more than 10 000 are estimated to be missing. Most hospitals are no longer able to function. Already, **diarrhoeal diseases, respiratory infections and hepatitis A, among others, are raging through Gaza**. Nearly everyone in Gaza is facing acute food insecurity and catastrophic hunger. Thousands of children are malnourished, making them even more susceptible to disease.

About 2.3 million people live in the 365 sq km (141 sq mile) Gaza Strip, which has become even more concentrated amid limited access to clean and safe water, and deteriorating sanitary conditions. Since early May, almost a million people have been relocated from Rafah to Khan Younis and Deir al-Balah, where the polio samples were detected.

While no cases of polio have been recorded yet, without immediate action, it is just a matter of time before it reaches the thousands of children who have been left unprotected. Children under five years are at risk, and especially infants under two because many have not been vaccinated over the nine months of conflict.

The World Health Organization (WHO) is sending more than 1m polio vaccines to Gaza, which will be administered in the coming weeks to prevent children being struck down by the disease. However, **without an immediate ceasefire and a vast acceleration of humanitarian aid, including a targeted vaccination campaign focused on young children, people will continue to die from preventable diseases** and injuries that are treatable...

Now, children trapped in Gaza face this same threat and are left with nowhere to turn. **Prior to the conflict, vaccination coverage was at 99%. Now that rate has dropped to 86%, which is dangerous as this provides pockets of unvaccinated children, where the virus can circulate.**

The decimation of the health system, lack of security, destruction of infrastructure, mass displacement of people and shortage of medical supplies have prevented children from receiving many lifesaving vaccines...

In the face of profound peril and hardship, the international community has a responsibility to leave no one behind and prioritize health and well-being. This is not unprecedented – **from El Salvador's civil war in the 1980s to conflict in Sudan's Darfur region in the early 2000s, ceasefires, called "days of tranquility", have been negotiated to essentially put wars on pause and ensure life-saving vaccines reach communities trapped in inaccessible, conflict-affected areas.**

Today, the detection of polio in Gaza is yet another sobering reminder of the dire conditions that people are facing. Continued conflict will not only add to the rising death toll in the territory, but it will hamper efforts to identify and respond to preventable health threats like polio.

While immediate efforts to reach every child with polio vaccines are now being put into motion, ultimately, a ceasefire and free-flowing aid are the only definite ways to protect people and prevent an explosive outbreak

.....

[Regional Health Ministers rally to support immediate steps to stop polio from paralyzing children in the Gaza Strip](#)

26 July 2024, Cairo, Egypt - Health ministers from across the Eastern Mediterranean Region have united to address the polio emergency in the occupied Palestinian territory.

The urgent need for coordinated, collective regional action to combat circulating variant poliovirus type 2 (cVDPV2) in the Gaza Strip was the focus of the 11th meeting of the Regional Subcommittee on Polio Eradication and Outbreaks. WHO Regional Director for the Eastern Mediterranean Dr Hanan Balkhy convened the meeting, held virtually on 25 July 2024.

The confirmation of poliovirus adds to the multiple threats faced today by children in the Gaza Strip, who had access to robust routine vaccination services prior to the war - and raises concerns about the potential for widespread poliovirus transmission and paralytic polio. While an estimated 99% of children in the occupied Palestinian territory received their third dose of polio vaccine in 2022, this fell to 89% in 2023 according to the latest routine immunization estimates by WHO and the United Nations Children's Fund (UNICEF)

Reflecting on her recent visit to the Gaza Strip, Dr Balkhy advocated for joint actions to urgently halt further spread of polio. "I witnessed at first hand living conditions that are highly favourable for the spread of polio and other diseases. This is an important time for the Subcommittee to come together to act swiftly and decisively to contain this outbreak, for the children of Gaza."

In attendance at the meeting were health ministers from Member States of the Eastern Mediterranean Region, Global Polio Eradication Initiative partners and the UNICEF regional directors for the Middle East and North Africa and South Asia.

Meeting participants were updated on the polio situation in the Gaza Strip. The participants then unanimously called on stakeholders and leaders across the Eastern Mediterranean Region, including parties to the conflict in the occupied Palestinian territory, to **advocate strongly and immediately to ensure a safe and enabling environment, by way of a ceasefire or days of tranquility, to allow for steps to be taken to stop polio from paralyzing children in Gaza, and surrounding areas and countries.**

These steps include intensified surveillance, multiple mass polio immunization campaigns that can be integrated with other crucial health service delivery when feasible, and enhanced community engagement to ensure that every child is protected.

Dr. Maged Abu Ramadan, the Minister of Health from the occupied Palestinian territory acknowledged the risks to the health of the population, particularly children, in Gaza and requested the support of Member States in building up their surveillance capacity on the ground to ensure any presence of

poliovirus is detected promptly, along with laboratory support for testing environmental and human samples in neighboring countries of WHO's Eastern Mediterranean Region.

The ministers of health emphasized the urgency for a coordinated regional effort to support the response in Gaza and surrounding countries, which would translate into a joint, robust regional poliovirus outbreak prevention and response plan. Offers of technical, logistic and laboratory support for ongoing testing of human and environmental samples from the Gaza Strip were pledged by Iraq, Jordan, Kingdom of Saudi Arabia, and Syria.

The Subcommittee also addressed the urgent need to stop all forms of poliovirus in the Eastern Mediterranean Region. It is home to the last two countries in the world with endemic wild poliovirus transmission – Afghanistan and Pakistan. Countries of the region are also facing active variant poliovirus outbreaks, such as in Somalia, Sudan and Yemen...

.....

Polio this week as of 31 July 2024 - GPEI

Headlines

:: This week, the Global Polio Eradication Initiative (GPEI) launched Team End Polio, a new campaign to unite fans everywhere around a common goal: to end polio for good. [Read more...](#)

Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: 11 WPV1-positive environmental samples
- Chad: one cVDPV2 case and one positive environmental sample
- Guinea: one cVDPV2 case
- Liberia: two cVDPV2 positive environmental samples
- Niger: three cVDPV2 positive environmental samples
- Nigeria: six cVDPV2 cases and three positive environmental samples
- Occupied Palestinian Territory : six cVDPV2 positive environmental samples
- Sierra Leone: one cVDPV2 positive environmental sample
- Yemen: one cVDPV2 case

.....

BE RECEIVES WHO's PQ FOR THEIR NOVEL ORAL POLIO VACCINE

nOPV2 is a next-generation oral vaccine developed to combat cVDPV2 outbreaks

Hyderabad, July 30, 2024: In a monumental stride towards eradicating polio worldwide, Biological E. Limited (BE), a Hyderabad-based vaccine and pharmaceutical company today announced that the World Health Organisation (**WHO**) **has granted Pre-qualification (PQ) status to their Novel Oral Polio Vaccine type 2 (nOPV2).** nOPV2 is the 10th pre-qualified vaccine of BE. This next-generation live, attenuated oral vaccine significantly reduces the risk of circulating vaccine-derived Poliovirus type 2 (cVDPV2) outbreaks and it is aimed at immunisation in countries that are affected by cVDPV2 outbreaks, which is a crucial moment in the fight against polio.

The persistent threat of circulating vaccine-derived Poliovirus type 2 (cVDPV2) outbreaks can be tackled with the use of nOPV2 as the vaccine of choice. **With its improved genetic stability, nOPV2 has a significantly decreased chance of seeding new outbreaks in low-immunity environments** as against its predecessor, the Sabin poliovirus type 2 (mOPV2) vaccine.

Extensive clinical trials have rigorously evaluated the safety and immunogenicity of nOPV2, leading to promising results published in The Lancet (2019-2024). Furthermore, the vaccine's real-world

deployment in outbreak regions has shown that it can significantly decrease the incidence of cVDPV2 outbreaks, safeguarding communities from the ravages of polio.

BE has become an important player in the production of the nOPV2 vaccine, having been selected for a grant from the Bill and Melinda Gates Foundation (BMGF) to assist in meeting the growing global demand. In collaboration with PT Bio Farma (PTB) in Indonesia, the first manufacturer of the nOPV2 vaccine to receive WHO Pre-Qualification in January 2024, **BE has successfully received technology from PTB and qualified large-scale manufacturing facilities that produce more than 500 million doses of nOPV2 vaccine annually. BE has been approved by the Indian regulatory authorities to manufacture the vaccine for export purposes..**

Ms. Mahima Datla, Managing Director, Biological E. Limited, said, "We are pleased to be a part of the global effort to eradicate polio. Our collective quest to eradicate polio marks a significant milestone with the WHO pre-qualification of nOPV2. **This vaccine has been specifically designed to address concerns about Vaccine-Associated Paralytic Polio (VAPP), which has occurred in approximately 2 to 4 cases per million births with the traditional OPV due to the vaccine virus reverting to a virulent form.**"

Ms. Datla further expressed BE's gratitude for the collaboration with PT Bio Farma (PTB) and the support of a grant from the Gates Foundation, "Collaborating with PTB is a privilege and we extend our heartfelt gratitude to the Gates Foundation for entrusting us with the responsibility of manufacturing nOPV2. Together we are committed to advancing the cause of global health equity and guaranteeing that no child is affected by the devastating effects of polio. The significance of this milestone extends beyond scientific achievement; it represents a beacon of hope for millions of children and families around the globe. **The achievement of administering over 1 billion doses of nOPV2 in outbreak regions is crucial to realizing the dream of a polio-free world."**

.....
.....

Global Pandemic Preparedness Summit 2024

July 29–30, Rio de Janeiro, Brazil

CEPI Media Release

RIO DE JANEIRO, 30 July 2024: The Global Pandemic Preparedness Summit 2024, co-hosted by Brazil's Ministry of Health, Fundação Oswaldo Cruz (Fiocruz) and CEPI, **concluded today in Rio de Janeiro with a strong call for global leaders to reignite efforts to transform the world's ability to prepare and respond to future pandemics.**

Amid the heightened risk of new deadly disease outbreaks that can strike anywhere at any time, **350 experts from governments, civil society, industry and health organisations around the world gathered at the Summit—held during Brazil's 2024 G20 presidency—to harness scientific progress and political will to reinvigorate momentum around the pandemic preparedness agenda.**

Spanning two days of discussions from over 80 expert speakers, **the landmark event discussed lessons from COVID-19** and the progress made and challenges faced as the world strives to be better prepared to face down future pandemic threats rapidly and equitably.

Conversations centred around efforts to ramp up disease surveillance, regional manufacturing and access to health tools and countermeasures that could combat epidemic and pandemic threats in as little as 100 days. The ambitious 100 Days Mission, spearheaded by CEPI and embraced by G7 and G20

nations, seeks to develop vaccines, diagnostics and therapeutics against a novel viral threat in just over a three-month period...

Other discussions delved into whether the world is ready for a zoonotic influenza pandemic, how climate change is heightening epidemic risk, pandemic financing and the latest developments with the Pandemic Agreement negotiations.

In recognition of the need for strengthened preparedness and greater equity, organisations based in the Global South signed the **Rio de Janeiro Declaration at the Summit**. **The statement, spearheaded by Fiocruz, calls for greater collaboration between partners within the Global North and Global South to overcome disparities in access to health tools and countermeasures in low- and middle-income countries.** The Declaration also urges global health partners to prioritise research and equitable access policies to focus on end-to-end R&D and support the establishment of the Alliance for Regional and Local Production, Innovation and Access, as discussed within Brazil's G20 Presidency framework.

Other important pandemic preparedness developments from the Summit include:

:: Summit co-host Brazil's Bio-Manguinhos/Fiocruz has joined CEPI's growing network of vaccine producers in the Global South. As a member of the vaccine manufacturing network, CEPI will support Bio-Manguinhos/Fiocruz to boost and expand its local vaccine production efforts to support more rapid, agile and equitable responses to public health disease outbreaks in the region.

:: Summit partner FIND has launched the Pathogen Diagnostic Readiness Index (PDxRI), a comprehensive tool for evaluating diagnostic preparedness by assessing the global availability of diagnostics for 21 pathogens with outbreak-, epidemic- and pandemic potential. Developed by FIND and OneTandem, the Index will enable the global community to make informed decisions, allocate resources and implement targeted interventions to scale up global diagnostic capacity.

:: The Regionalized Vaccine Manufacturing Collaborative, an initiative supported by CEPI, the World Economic Forum and the US National Academies of Medicine, **has announced its new strategy** to support the establishment of regional vaccine manufacturing and supply chain networks to produce vaccines for routine use, with readiness for manufacturing of outbreak vaccines.

:: A new clinical trial, funded by CEPI and the Canadian Institutes of Health Research, will take place in the Democratic Republic of Congo and neighbouring countries **assessing whether post-exposure vaccination could protect against mpox.** Evidence generated could be crucial in shaping mpox vaccination strategies to help tackle a large and deadly outbreak escalating in the region.

:: CEPI and ISARIC have outlined their collaboration to align research across vaccines and therapeutics to streamline their activities and accelerate the response to future disease threats.

:::::
:::::

Pathogen Research

Pathogens prioritization: a scientific framework for epidemic and pandemic research preparedness

WHO R&D Blueprint Health Emergencies Program
30 July 2024 | Meeting report :: 73 pages


PDF: <https://www.who.int/publications/m/item/pathogens-prioritization-a-scientific-framework-for-epidemic-and-pandemic-research-preparedness>

Released at the Global Pandemic Preparedness Summit 2024 held in Rio de Janeiro, Brazil, this week, **this report urges a broader-based approach by researchers and countries with a framework to help steer and coordinate research into entire pathogen families**, a strategy that aims to bolster the world's ability to swiftly respond to unforeseen variants, emerging pathogens, zoonotic spillover, and unknown threats referred to as pathogen X.

Executive Summary [excerpts]

The WHO R&D Blueprint for Epidemics has a primary goal to accelerate the development of medical countermeasures (MCMs). Since 2015, its primary goal is to make these countermeasures available for diseases with epidemic and pandemic potential, thereby contributing to the prevention of Public Health Emergencies of International Concern (PHEICs) and saving lives during outbreaks.

Figure 1. Overview of the prioritization process within each of the FEGs



*Independent Family Expert Groups (FEGs) examined the evidence and reviewed individual Families and pathogens, and the scientific knowledge gaps that need to be addressed.
[Original graphic from report of marginal quality]*

The WHO R&D Blueprint for Epidemics functions as a global platform for research and development collaboration, stressing the significance of international cooperation in expediting the research and development of medical countermeasures (MCMs) to respond to epidemics and pandemics. At the core of its efforts lies the concept of 'pathogen prioritization'. **This document outlines the findings of a**

global pathogen prioritization process involving over 200 scientists from more than 50 countries who evaluated the evidence related to 28 Viral Families and one core group of Bacteria, encompassing 1,652 pathogens. This process emphasized the imperative nature of collaborative efforts to attain global resilience against epidemics and pandemics...

...It is equally important in considering the entire value chain to take a broader view that recognizes the primary importance of quality, equity in access, and trust in the product's safety and efficacy. Preparations and implementation of pandemic response thus should be country-centered, transparent, and collaborative.

By prioritizing research on entire pathogen Families as opposed to a handful of individual pathogens, **this strategy bolsters the capability to respond efficiently to unforeseen variants, emerging pathogens, zoonotic transmissions, and unknown threats such as 'Pathogen X.'** It also emphasizes the need for prompt identification and characterization of emerging threats, the streamlining of global R&D efforts, via collaborative and efficient research roadmaps and the integration of research into outbreak and pandemic response.

The widespread geographic distribution of the viral and bacterial families and pathogens identified in this report, with several known to circulate across diverse nations and regions globally, underscores the pivotal role of global initiatives in linking national and regional research actions.

Significantly, the strategy advocates for decentralized collaborative approaches and supporting research efforts in areas critical for pandemic research preparedness. This comprehensive approach aims to foster international collaboration by establishing a global framework for researchers, developers, policymakers, funders, manufacturers, and institutions, fostering a collaborative space to advance research across all Viral and Bacterial Families, as well as R&D for Priority and Prototype pathogens.

.....

[CEPI and WHO urge broader research strategy for countries to prepare for the next pandemic](#)

1 August 2024 *Joint News Release*


The Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO) today called on researchers and governments to strengthen and accelerate global research to prepare for the next pandemic.

They emphasized the importance of expanding research to encompass entire families of pathogens that can infect humans—regardless of their perceived pandemic risk—as well as focusing on individual pathogens. The approach proposes using prototype pathogens as guides or pathfinders to develop the knowledge base for entire pathogen families...

This approach aims to create broadly applicable knowledge, tools and countermeasures that can be rapidly adapted to emerging threats. This strategy also aims to speed up surveillance and research to understand how pathogens transmit and infect humans and how the immune system responds to them.

The report's authors likened its updated recommendation to imagining scientists as individuals searching for lost keys on a street (the next pandemic pathogen). The area illuminated by the streetlight represents well-studied pathogens with known pandemic potential. By researching prototype pathogens, we can expand the lighted area, gaining knowledge and understanding of pathogen families that might currently be in the dark. The dark spaces in this

metaphor include many regions of the world, particularly resource-scarce settings with high biodiversity, which are still under monitored and understudied. These places might harbour novel pathogens, but lack the infrastructure and resources to conduct comprehensive research...



The prioritization work underpinning the report involved over 200 scientists from more than 50 countries, who evaluated the science and evidence on 28 virus families and one core group of bacteria, encompassing 1652 pathogens. The epidemic and pandemic risk was determined by considering available information on transmission patterns, virulence, and availability of diagnostic tests, vaccines, and treatments.

CEPI and WHO also called for globally coordinated, collaborative research to prepare for potential pandemics...

To facilitate this, **WHO is engaging research institutions across the world to establish a Collaborative Open Research Consortium (CORC) for each pathogen family**, with a WHO Collaborating Centre acting as the research hub for each family. These CORCs around the world will involve researchers, developers, funders, regulators, trial experts and others, with the aim to promote greater research collaboration and equitable participation, particularly from places where the pathogens are known to or highly likely to circulate.

.....
.....

Defining access to countermeasures: landscape report: executive summary

WHO 31 July 2024 | *Executive summary*

Download (1.6 MB)

Overview

This landscape report on the current status of activities related to medical countermeasures (MCMs) for pandemic response underscores the urgent need for action in this critical area. From bolstering research and development to diversifying manufacturing capacities, coordinating global procurement efforts, ensuring equitable allocation approaches for these lifesaving interventions, and making sure arrangements are in place so that they reach the very last mile and enable appropriate use by those in need, the journey toward pandemic preparedness traverses a multifaceted landscape.

Yet, despite the progress made, critical gaps in MCM-related aspects remain, and vulnerabilities urgently need to be addressed. This report explores scientific advancements and ongoing or planned activities in the field of MCMs. While there is much progress to note and acknowledge, it is evident that significant work remains to strengthen our abilities to prepare for and respond to pandemics.

Moreover, no single entity can tackle this monumental task alone. A network of networks is needed, wherein collaboration and coordination among regional and global health actors are strengthened, ensuring a coherent, streamlined, and accountable approach to pandemic preparedness. This report emphasizes the importance of collective effort in navigating the complex landscape of medical countermeasures and enhancing global health security.

.....
.....

New initiative launched to advance mRNA vaccine development against human avian influenza (H5N1)

29 July 2024 *Joint News Release*

Geneva, Switzerland

A new project aiming to accelerate the development and accessibility of **human avian influenza (H5N1) messenger RNA (mRNA) vaccine candidates for manufacturers in low- and middle-income countries** has been launched today.

The Argentinian manufacturer Sinergium Biotech will lead this effort leveraging the World Health Organization (WHO) and the Medicines Patent Pool (MPP) mRNA Technology Transfer Programme.

The mRNA Technology Transfer Programme, jointly developed by WHO and MPP, was launched in July 2021 with the aim to build capacity in low- and middle-income countries (LMICs) for the development and production of mRNA-based vaccines. **Sinergium Biotech, a partner in the mRNA Technology Transfer Programme, has developed candidate H5N1 vaccines and aims to establish proof-of-concept in preclinical models.** Once the preclinical data package is concluded, the technology, materials, and expertise will be shared with other manufacturing partners, aiding the acceleration of the development of H5N1 vaccine candidates, and bolstering pandemic preparedness efforts.

"This initiative exemplifies why WHO established the mRNA Technology Transfer Programme – to foster greater research, development and production in low- and middle-income countries, so that when the next pandemic arrives, the world will be better prepared to mount a more effective and more equitable response," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.

"When we created the mRNA Technology Transfer Programme with WHO, our goal was to enable low- and middle-income countries to lead development efforts, foster collaboration, share resources, and disseminate knowledge," said Charles Gore, Executive Director of MPP.

"This project embodies our vision and demonstrates a strong commitment to future pandemic preparedness and response."

Avian influenza viruses are a significant public health risk due to their widespread circulation in animals and potential to cause a future pandemic. This development supplements ongoing work under the Pandemic Influenza Preparedness Framework to improve and strengthen the sharing of influenza viruses with human pandemic potential and increasing LMIC access to vaccines...

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

WHO & Regional Offices [to 03 Aug 2024]

<https://www.who.int/news>

Selected News/Announcements/Statements

1 August 2024 *Joint News Release*

[CEPI and WHO urge broader research strategy for countries to prepare for the next pandemic](#)

31 July 2024 *Statement*

[On World Breastfeeding Week, UNICEF and WHO call for equal access to breastfeeding support](#)

30 July 2024 *News release*

[WHO and United Arab Emirates evacuate 85 patients from Gaza](#)

29 July 2024 *News release*

[Adolescent girls face alarming rates of intimate partner violence](#)

29 July 2024 *Joint News Release*

[New initiative launched to advance mRNA vaccine development against human avian influenza \(H5N1\)](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

:: 28 July 2024

[Eliminating mother-to-child transmission of HIV and hepatitis B](#)

:: 26 July 2024

[Protecting children against hepatitis B with birth-dose vaccine](#)

WHO Region of the Americas PAHO

:: 2 Aug 2024

[PAHO urges countries to strengthen prevention, surveillance and diagnosis of the Oropouche virus following its geographic spread and recent clinical findings](#)

Washington, DC, 2 August 2024 (PAHO) – The Pan American Health Organization (PAHO) has issued an epidemiological alert calling on countries to strengthen surveillance and implementation of laboratory diagnosis of the Oropouche virus (OROV). The call follows a recent increase in cases, and spread of the disease to new areas, as well as reports...

:: 1 Aug 2024

[PAHO and Unitaidd sign agreement to intensify collaboration to prevent and advance HIV response in Latin America and the Caribbean](#)

Rio de Janeiro, 31 July 2024 (PAHO) - The Pan American Health Organization (PAHO) and global health initiative Unitaid have signed a Memorandum of Understanding to intensify collaboration to advance HIV response in Latin America and the Caribbean. The US\$ 5 million grant, which was signed in Rio de Janeiro, Brazil, on 30 July, aims to reduce HIV...

:: 30 Jul 2024

Addressing health equity is key to ensuring better pandemic preparedness, PAHO Director says

Rio de Janeiro, 30 July 2024 (PAHO) – Addressing inequality and ensuring equitable access to health were key issues raised by Pan American Health Organization Director (PAHO), Dr. Jarbas Barbosa, during a high-level event at the Global Pandemic Preparedness Summit 2024, in Rio de Janeiro Brazil. "We all know that poverty and disease is a vicious...

:: 29 Jul 2024

New initiative launched to advance mRNA vaccine development against human avian influenza (H5N1)

29 July 2024, Geneva, Switzerland — A new project aiming to accelerate the development and accessibility of human avian influenza (H5N1) messenger RNA (mRNA) vaccine candidates for manufacturers in low- and middle-income countries has been launched today. The Argentinian manufacturer Sinergium Biotech will lead this effort...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

No new digest content identified.

WHO Eastern Mediterranean Region EMRO

No new digest content identified.

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations.

No new digest content identified.

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

31 July 2024 | Antimicrobial Resistance, Hypervirulent Klebsiella pneumoniae - Global situation

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 99, Nos. 30/31, pp. 395–406 26 July 2024

PDF: <https://iris.who.int/bitstream/handle/10665/378268/WER9930-31-eng-fre.pdf>

Reviewed earlier

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected

1 August 2024

[Training on Influenza Data Management and Basic Analysis: Maldives 2023](#)

31 July 2024

[Defining access to countermeasures: landscape report: executive summary](#)

30 July 2024

[International travel and health - module 1: general health risks and considerations for travellers](#)

30 July 2024

[Establishing a behavioural insights function: decision support tool](#)

30 July 2024

[World Local Production Forum on enhancing access to medicines and other health technologies: report of...](#)

29 July 2024

[Medical device donations: considerations for solicitation and provision. Second edition](#)

.....

.....

USA – HHS, FDA, CDC

HHS

News

[Biden-Harris Administration Announces More Than \\$68 Million to Improve Access to HIV Care for Women, Infants, Children and Youth](#)

July 31, 2024 *News Release*

FDA

Press Announcements

No new digest content identified.

FDA VRBPAC

Advisory Committee Calendar

No meetings appear on calendar.

CDC/ACIP [U.S.] [to 03 Aug 2024]

<http://www.cdc.gov/media/index.html>

Latest News

No new digest content identified.

ACIP Meetings

Next ACIP Meeting
October 23-24, 2024

MMWR Weekly

<https://www.cdc.gov/mmwr/index2023.html>

August 1, 2024 / No. 30

[PDF of this issue](#)

No new digest content identified.

.....
.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

[EMA supports pilot for joint African continental assessment procedures](#)

Validating processes is an important step towards establishment of African Medicines Agency

30 July 2024

EMA has awarded a grant to the African Medicines Regulatory Harmonisation (AMRH) initiative of the African Union Development Agency (AUDA-NEPAD) to support a pilot to test procedures for the joint continental evaluation of medicines in Africa.

AUDA-NEPAD has been working on harmonisation activities for a decade, paving the way for the creation of the African Medicines Agency (AMA). The launch of the continental pilot is one of these activities that aim to validate procedures and processes ahead of the establishment of the AMA. The pilot, which is co-funded with the Bill & Melinda Gates Foundation, will run for a year.

During the pilot, the AMRH Evaluation of Medicinal Products Technical Committee (EMP-TC) will evaluate the quality, safety and efficacy of priority medicinal products with the support of the continental Good Manufacturing Practices Technical Committee (GMP-TC). The learnings from the evaluations will help to develop continental processes and procedures, facilitate national authorisations of recommended medicines and strengthen information sharing and reliance...

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

[Risk to EU/EEA from variant mpox virus 'very low'](#)

29 Jul 2024

Surveillance and monitoring

[Surveillance of West Nile virus infections in humans, weekly report](#)

1 Aug 2024

Weekly update with the latest reports on West Nile virus cases in Europe.

.....
.....

Africa CDC [to 03 Aug 2024]

<https://africacdc.org/>

Press Releases, Statements [Selected]

Statement

The Permanent Representatives Committee of the African Union Provides Emergency Approval of \$10.4 Million to Africa CDC for Mpox Outbreak Response

Addis Ababa, Ethiopia, August 2, 2024: The Permanent Representatives Committee (PRC) of the African Union (AU) has made emergency approval of \$10.4 million from the existing COVID funds for the Africa Centres for Disease Control and Prevention (Africa CDC) to support ongoing efforts to combat the Mpox outbreak across the continent.

From January to July 2024, 15,074 Mpox cases (2,853 confirmed; 12,221 suspected) and 461 deaths (a case fatality rate of 3.06%) have been reported across Twelve (12) AU Member States. This represents a 160% increase in cases and a 19% increase in deaths in 2024 compared to the same period in 2023.

The funding released by the PRC will complement national efforts by African Governments and support from various partners to strengthen five critical areas in the fight against Mpox...

Africa CDC News

Outbreak Report, 30 July 2024: Mpox Situation in Africa

31 July 2024

I- Current Situation

Mpox in Africa: Since the beginning of 2022 and as of 28 July 2024, a total of 37,583 cases and 1,451 deaths (case fatality rate [CFR]: 3.9%) of mpox have been reported from 15 African Union Member States (AU MS): Benin, Burundi, Cameroon, Central Africa Republic (CAR), Congo, Democratic Republic of Congo (DRC), Egypt, Ghana, Liberia, Morocco, Mozambique, Nigeria, Rwanda, Sudan and South Africa (see table 1). In 2023 alone, 14,957 cases and 739 deaths (CFR: 4.9%) were reported from seven AUMS. This is a 78.5% increase in the number of new cases compared to 2022...

.....
.....

China CDC

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 03 Aug 2024]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 03 Aug 2024]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (6)

2024-08-02 / No. 31

[PDF of this issue](#)

No new digest content identified.

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

[:: Organization Announcements](#)

[:: Journal Watch](#)

[:: Pre-Print Servers](#)

.....

.....

Organization Announcements

Paul G. Allen Frontiers Group [to 03 Aug 2024]

<https://alleninstitute.org/news-press/>

News

[Allen Institute partners to bring open science to Africa](#)

08.02.2024

Computational neuroscience course, built on Allen Institute tools and data, aimed to empower next-gen researchers in Africa.

BMGF - Gates Foundation [to 03 Aug 2024]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 03 Aug 2024]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 03 Aug 2024]

<https://carb-x.org/>

News

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 03 Aug 2024]

<http://cepi.net/>

Latest News

News

News

[Scientists explore innovative tech to rapidly make new vaccine antigens](#)

1 Aug 2024

News

[CEPI and WHO urge broader research strategy for countries to prepare for the next pandemic](#)

31 Jul 2024

News

[Global Summit reinvigorates efforts to prepare for future pandemics](#)

29 Jul 2024

News

[Creating sustainable pathways to regional vaccine manufacturing](#)

28 Jul 2024

News

[Mobilising Brazil's manufacturing might to support vaccine production in the Global South](#)

28 Jul 2024

News

[New trial to assess if mpox vaccination works after virus exposure](#)

27 Jul 2024

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 03 Aug 2024]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 03 Aug 2024]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 03 Aug 2024]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [to 03 Aug 2024]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

31 July 2024

[EDCTP Annual Report 2023: two decades and beyond](#)

Emory Vaccine Center [to 03 Aug 2024]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 03 Aug 2024]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Evidence Aid [to 03 Aug 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

Resources [Selected]

Medical and Psychosocial Care of Paediatric Refugees

Added July 27, 2024

Access to and engagement with health services among disadvantaged populations

Added July 26, 2024

mHealth applications for the 2014-2015 West Africa Ebola outbreak

Added July 25, 2024

Fondation Merieux [to 03 Aug 2024]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 03 Aug 2024]

<https://www.gavi.org/>

Press Releases

No new digest content identified.

GE2P2 Global Foundation [to 03 Aug 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – June 2024](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 25 July 2024 – Issue 21](#)

GHIT Fund [to 03 Aug 2024]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 03 Aug 2024]

<https://www.theglobalfund.org/en/news/>

News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 03 Aug 2024]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 03 Aug 2024]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 03 Aug 2024]

<https://www.hhmi.org/news>

Press Room

[Janelia Names Nelson Spruston Its Third Executive Director](#)

August 01, 2024

[Nelson Spruston](#) has been named the next Executive Director of HHMI's [Janelia Research Campus](#), [opens in a new tab](#) and an HHMI Vice President. His appointment begins August 1.

Human Immunome Project [nee Human Vaccines Project] [to 03 Aug 2024]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [to 03 Aug 2024]

<https://www.iavi.org/>

News, Features

IAVI Report

[Another inflection point in the HIV/AIDS response](#)

July 31, 2024

Last week at AIDS 2024 many experts warned that the global response is at a critical inflection point. Will efforts to develop and provide access to new prevention options drive much-needed progress?

INSERM [to 03 Aug 2024]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 03 Aug 2024]

<https://www.ich.org/>

News/Pubs/Press Releases [Selective]

Call for Public Comment: General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies that Utilize Real-World Data for Safety Assessment of Medicines.

The guideline will focus on non-interventional pharmacoepidemiological studies using Real-World Data (RWD) and will include basic principles that may apply to these studies when real-world data elements are included.

Public consultation dates [announced to date]:

NMPA, China - Deadline for comments by 12 October 2024

TFDA, Chinese Taipei - Deadline for comments by 30 September 2024

ANVISA, Brazil - Deadline for comments by 24 August 2024

MHLW/PMDA, Japan - Deadline for comments by 28 July

Republic of Korea - Deadline for comments by 15 July 2024

ICRC [to 03 Aug 2024]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 27 July 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

Red Cross calls for support as Ethiopia faces its deadliest landslides

02/08/2024 | *Press release*

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

No new digest content identified.

Institut Pasteur [to 03 Aug 2024]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

ISC / International Science Council [to 03 Aug 2024]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

No new digest content identified.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

No new digest content identified.

IVAC [to 03 Aug 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 03 Aug 2024]

<http://www.ivi.int/>

IVI News & Announcements

No new digest content identified.

Johns Hopkins Center for Health Security [to 03 Aug 2024]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 03 Aug 2024]

<http://www.msf.org/>

Latest [Selected Announcements]

Democratic Republic of Congo

[**Five questions about the mpox outbreak in DRC**](#)

Interview 30 Jul 2024

Gaza-Israel war

[**Nasser hospital must be protected as south Gaza hospitals receive waves of deadly influxes**](#)

Press Release 29 Jul 2024

National Academy of Medicine - USA [to 27 July 2024]

<https://nam.edu/programs/>

News [Selected]

[**NAM & New England Journal of Medicine Launch New Series**](#)

August 1, 2024

The National Academy of Medicine (NAM) and the New England Journal of Medicine (NEJM) have partnered to launch a new series designed to bring evidence-based policy insights to the NEJM readership. The From the National Academy of Medicine series will distill findings and recommendations from reports of the NAM and the National Academies of Sciences, Engineering, and Medicine to inform scientific and clinical practice as well as public policies that impact health...

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 27 July 2024]

<https://www.nationalacademies.org/newsroom?>

News

[Exploring the Implications of AI for Climate](#)

Feature Story | August 2, 2024

By [Sara Frueh](#)

National Vaccine Program Office - U.S. HHS [to 03 Aug 2024]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 03 Aug 2024]

<http://www.nih.gov/>

News Releases

No new digest content identified.

PATH [to 03 Aug 2024]

<https://www.path.org/media-center/>

Newsroom

No new digest content identified.

Sabin Vaccine Institute [to 03 Aug 2024]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 03 Aug 2024]

<http://www.unaids.org/en>

News, Stories, Updates

Press release

[UNAIDS urges leaders to 'act now' to overcome the world's deadliest pandemic at AIDS 2024](#)

GENEVA/MUNICH, 26 July 2024—At the 25th International AIDS Conference (#AIDS2024), UNAIDS urged all participants to stay committed because the end of AIDS is within grasp. UNAIDS called on leaders to embrace new scientific developments to prevent HIV, ensure that the work to end AIDS is fully resourced, and to 'stand for justice' to end harmful laws preventing people from accessing lifesaving HIV services.

On the first day of the conference, UNAIDS released a new report, '[The Urgency of Now: AIDS at a Crossroads](#)' showing that the decisions taken by world leaders this year will decide the fate of millions of people and determine whether world leaders will meet their commitment to end AIDS as a public health threat by 2030. Data from the report was used to highlight this critical message in sessions and plenaries throughout the conference...

UNICEF [to 03 Aug 2024]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

Press release 01 August 2024

Famine confirmed in Sudan's North Darfur, confirming UN agencies worst fears

ROME/NEW YORK/PORT SUDAN, 1 August 2024 – After more than 15 months of war in Sudan, a catastrophic combination of conflict, displacement and humanitarian access constraints has resulted in famine in a camp sheltering hundreds of thousands of displaced people in Sudan's North Darfur Region. The Famine Review Committee (FRC)'s conclusion that there...

Statement 31 July 2024

This World Breastfeeding Week, UNICEF and WHO call for equal access to breastfeeding support

NEW YORK/GENEVA, 1 August 2024 – "In the last 12 years, the number of infants under six months of age globally who are exclusively breastfed has increased by more than 10 per cent. This means 48 per cent of infants worldwide now benefit from this healthy start in life. It translates to hundreds of thousands of babies whose lives have been saved by...

Unitaid [to 03 Aug 2024]

<https://unitaid.org/>

Featured News

Featured News

01 August 2024

PAHO and Unitaid sign agreement to intensify collaboration to prevent and advance HIV response in Latin America and the Caribbean

The US\$ 5 million grant, which was signed in Rio de Janeiro, Brazil, on 30 July, aims to reduce HIV deaths in the region by addressing the prevention and management of advanced HIV disease.

31 July 2024

Unitaid welcomes the Rio Declaration, which aims to advance health sovereignty and innovation in the Global South

Geneva/Rio de Janeiro – The second Global Pandemic Preparedness Summit, held in Rio de Janeiro on 29 and 30 July 2024, underscored the urgent need to address global asymmetries in access to health tools and services, as reflected in the Rio de Janeiro Declaration on Health Sovereignty in Innovation and Development of Diagnostics, Vaccines, and Medications for Public Health Emergencies in the Global South (Rio Declaration). It identified the critical need for equitable access to lifesaving medical innovations in the Global South, which aligns deeply with Unitaid's mission.

Vaccine Equity Cooperative [nee Initiative] [to 03 Aug 2024]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 03 Aug 2024]

<https://www.vaccineacceptance.org/>

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 03 Aug 2024]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 03 Aug 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

Vaccine Update for Providers - July 2024

Announcements: Fall webinar registration open, program changes reminder

September webinar registration now open

The next “Current Issues in Vaccines” webinar is scheduled for Sept. 11, 2024, at noon ET. Dr. Offit will be joined by Dr. Lori Handy to discuss the June ACIP meeting in a presentation titled, “Implementing ACIP Recommendations this Fall.” [Find out more or register today...](#)

Wellcome Trust [to 03 Aug 2024]

<https://wellcome.org/news/all>

News. Opinion, Reports

No new digest content identified.

The Wistar Institute [to 03 Aug 2024]

<https://www.wistar.org/news/press-releases>

Press Releases

Wistar to Honor 2023 Nobel Prize Winner Dr. Katalin Karikó

Helen Dean King Award Ceremony Recognizes the Power of Women in Science

PHILADELPHIA — (July 25, 2024) — The Wistar Institute honors 2023 Nobel Prize laureate in Physiology or Medicine Katalin Karikó, Ph.D., as the 2024 Helen Dean King Award recipient. Dr. Karikó, professor at the University of Szeged in Hungary and adjunct professor of Neurosurgery at the University of Pennsylvania, is this year’s Helen Dean King Award winner and will speak at the annual event at noon (ET) at The Wistar Institute on October 8, 2024.

World Bank [to 03 Aug 2024]

<http://www.worldbank.org/en/news/all>

All News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 03 Aug 2024]

<https://www.wfpfa.org/>

Blog, Events

No new digest content identified.

World Medical Association [WMA] [to 03 Aug 2024]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest content identified.

World Organisation for Animal Health [OIE] [to 03 Aug 2024]

<https://www.oie.int/en/>

Press Releases, Statements
No new digest content identified.

.....
.....

ARM [Alliance for Regenerative Medicine] [to 03 Aug 2024]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 03 Aug 2024]

<https://www.bio.org/press-releases>

Press Releases

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 03 Aug 2024]

<http://www.dcvmn.org/>

News; Upcoming events

[ANNUAL GENERAL MEETING 2024](#)

October 16 - 18, 2024 São Paulo, Brazil

ICBA – International Council of Biotechnology Associations [to 03 Aug 2024]

<https://internationalbiotech.org/news/>

News

No new digest announcements identified.

IFPMA [to 03 Aug 2024]

<https://ifpma.org/>

News, Statements [Selected]

No new digest announcements identified.

International Alliance of Patients' Organizations – IAPO [to 03 Aug 2024]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [to 03 Aug 2024]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases - *No new digest announcements identified.*

Bavarian Nordic

Latest News - *No new digest announcements identified.*

Bharat Biotech

Press Releases - *No new digest announcements identified.*

BioCubaFarma – Cuba

Últimas Noticias - *No new digest announcements identified*

Biological E

News

BE RECEIVES WHO'S PQ FOR THEIR NOVEL ORAL POLIO VACCINE

nOPV2 is a next-generation oral vaccine developed to combat cVDPV2 outbreaks

July 30, 2024:

BioNTech

Press Releases - *No new digest announcements identified*

BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma

30 July 2024

:: BNT111 is based on BioNTech's fully owned FixVac platform and proprietary uridine mRNA-LPX technology

...BioNTech has developed a range of mRNA platforms to establish a novel class of therapeutics and vaccines aimed at improving the health of people worldwide. In oncology, BioNTech utilizes five mRNA platforms. Each platform is designed with the aim to address unique challenges in oncology. BioNTech's fully owned FixVac (Fix Combination Vaccine) platform candidates target specific cancer indications focusing on tumor-associated antigens which are shared by many cancer patients...

Boehringer

Press Releases -

Boehringer Ingelheim secures novel immune checkpoint inhibitor with acquisition of Nerio Therapeutics

Ingelheim, Germany and La Jolla, CA, USA, Mon, 07/29/2024 - 14:00

Today marks a significant step for Boehringer Ingelheim's immuno-oncology pipeline as the company is adding an innovative preclinical program with the acquisition of Nerio Therapeutics Inc. ("Nerio") for a total of up to USD 1.3 billion. Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio to achieve its aim of improving cancer patient outcomes.

CanSinoBIO

News - *Website not responding at inquiry*

CIGB

Latest News - No new digest announcements identified.

Cinnagen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

Curevac

News - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]
<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

29 July 2024

[**Arexvy, GSK's Respiratory Syncytial Virus \(RSV\) vaccine, receives positive European Medicines Agency CHMP opinion for adults aged 50-59 at increased risk for RSV disease**](#)

29 July 2024

[**GSK and Flagship Pioneering partner to discover novel medicines and vaccines**](#)

:: Collaboration brings together GSK disease area expertise and development capability with Flagship portfolio of 40+ biopatform companies

:: Initial phase to identify and accelerate promising scientific concepts for further research starting in respiratory and immunology

:: GSK and Flagship to jointly fund up to \$150 million upfront

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

Janssen/JNJ

Press Releases - No new digest announcements identified.

Merck

News releases

[**Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab \(MK-1654\), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants**](#)

July 23, 2024

Moderna

Press Releases - No new digest announcements identified

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified.

Pfizer

Recent Press Releases - No new digest announcements identified

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases

[Hepatitis A Prevention and Control Technology and Vaccination Conference Held in Beijing](#)
2024-07-29

On July 20, 2024, Sinovac Biotech Ltd. ("SINOVAC" or the "Company") and the China Foundation for Hepatitis Prevention and Control successfully jointly held the "Hepatitis A Prevention and Control Technology and Vaccination Conference" in Beijing. The speakers were experts in public health and epidemiology from China, Colombia, Belarus, Indonesia, and the Philippines. They shared views on epidemiological characteristics and immunization prevention strategies of hepatitis A in their own countries.

SK Biosciences

Press Releases - No new digest announcements identified

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases

August 1, 2024

[Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World's Most Clinically Advanced Tetravalent Shigella Vaccine Candidate](#)

Vector State Research Centre of Virology and Biotechnology

Home - Website not responding [404 error]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 15, 2023 Issue 2

<https://www.tandfonline.com/toc/uabr21/current>

ELSIcon Special Issue

[Reviewed earlier]

AMA Journal of Ethics

Volume 26, Number 7: E507-590 July 2024

<https://journalofethics.ama-assn.org/issue/harm-reduction-and-opioid-use-disorder>

Harm Reduction and Opioid Use Disorder

Despite severe punishments and high rates of inequitable incarceration, unprecedented numbers of opioid-related deaths persist in the United States. The US has implemented few policies that align needs of communities, needs of individuals with opioid use disorder (OUD), and clinical evidence. Evidence-based harm reduction practices hold promise to help advance domestic approaches to thinking of OUD treatment as a human right, but successful implementation of harm reduction interventions relies heavily on care continuity and can still be thwarted by a so-called "War on Drugs." This theme issue follows our August 2020 issue, [Opioids and Public Health](#), and specifically considers harm as a concept in need of careful, case-specific attention and reduction as an intervention or set of interventions that are part of a safety net to curb opioid-related morbidity and mortality.

American Journal of Human Genetics

Jul 11, 2024 Volume 111 Issue 7 p1241-1494

<https://www.cell.com/ajhg/current>

[This Month in The Journal](#)

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Clinical genome sequencing (cGS) can provide a precision diagnosis for individuals with a suspected rare genetic disease and can promote improved, personalized care. Despite recognition of the importance of cGS for reaching a diagnosis, individuals residing in areas with reduced resources have limited access to testing options. In a move towards equitable access to cGS, the iHope Program provided cGS to ~1,000 individuals with a suspected rare genetic disease and constrained access to molecular testing in either low- or middle-income countries (LMICs) or high-income countries (HICs).

American Journal of Infection Control

July 2024 Volume 52 Issue 7 p745-864

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

July 2024 Volume 67 Issue 1 p1-174

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

July 2024 114(7)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 111 (2024): Issue 1 (Jul 2024)

<https://www.ajtmh.org/view/journals/tpmd/111/1/tpmd.111.issue-1.xml>

[Reviewed earlier]

Annals of Internal Medicine

July 2024 Volume 177, Issue 7

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 333 August 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/333/suppl/C>

[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 03 Aug 2024)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 03 Aug 2024)

Assessment of expanded programme on immunization routine data quality in the upper east region of Ghana

Data quality is a major challenge for most health institutions and organizations across the globe. The Ghana Health Service, supported by other non-governmental organizations, has instituted various strategies...

Authors: Louis Jean Piu, Joseph Owusu-Marfo, Yaa Nyarko Agyeman, Augusta Soninour Kolekang and Jonathan Kissi

Citation: BMC Health Services Research 2024 24:886

Content type: Research Published on: 2 August 2024

Costs of the COVID-19 vaccination programme: estimates from the West Rand district of South Africa, 2021/2022

The COVID-19 vaccination programme in South Africa was rolled out in February 2021 via five delivery channels- hospitals, primary healthcare (PHC), fixed, temporary, and mobile outreach channels. In this study...

Authors: Ijeoma Edoke, Lineo Marie Matsela, Khumo Modiba, Yolandie Luther, Sharlene Govender, Thapelo Maotoe, Heena Brahmhatt, Pedro T. Pisa, Gesine Meyer-Rath and Jacqui Miot

Citation: BMC Health Services Research 2024 24:857

Content type: Research Published on: 29 July 2024

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 03 Aug 2024)

Predictive factors for COVID-19 severity and mortality in hospitalized children

Understanding the factors influencing disease progression and severity in pediatric COVID-19 cases is essential for effective management and intervention strategies. This study aimed to evaluate the discrimina...

Authors: Shima Mahmoudi, Babak Pourakbari, Erfaneh Jafari, Hamid Eshaghi, Zahra Movahedi, Hosein Heydari, Maryam Mohammadian, Mohammad Bagher Rahmati, Marjan Tariverdi, Zohreh Shalchi, Amene Navaeian and Setareh Mamishi

Citation: BMC Infectious Diseases 2024 24:757

Content type: Research Published on: 31 July 2024

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 03 Aug 2024)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 03 Aug 2024)

The impact of the COVID-19 pandemic on tuberculosis treatment outcomes in 49 high burden countries

The COVID-19 pandemic disrupted tuberculosis (TB) health services, including treatment support and access to drugs, as patients were not able to access health facilities. While the effect of this disruption on...

Authors: Vester Gunsaru, Marc Y. R. Henrion and C. Finn McQuaid

Citation: BMC Medicine 2024 22:312

Content type: Research Published on: 29 July 2024

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 03 Aug 2024)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 03 Aug 2024)

[The relationship between trust in federal oversight of vaccine safety and willingness to participate in COVID-19 clinical trials: a repeated measures study of Philadelphia residents \(September 2021 – March 2023\)](#)

The Coronavirus Disease 2019 (COVID-19) pandemic precipitated an urgent need for clinical trials to discover safe and efficacious treatments. We examined how COVID-19 experiences, clinical trial awareness, and...

Authors: Hyunmin Yu, José Bauermeister, Ufuoma Oyiborhoro, Knashawn Morales, Subhash Aryal, Karen Glanz, Antonia Villarruel and Stephen Bonett

Citation: BMC Public Health 2024 24:2059

Content type: Research Published on: 31 July 2024

BMC Research Notes

<http://www.biomedcentral.com/bmcresearchnotes/content>

(Accessed 03 Aug 2024)

[No new digest content identified]

BMJ Evidence-Based Medicine

August 2024 - Volume 29 - 4

<https://ebm.bmj.com/content/29/4>

[Reviewed earlier]

BMJ Global Health

July 2024 - Volume 9 - 7

<https://gh.bmj.com/content/9/7>

[Reviewed earlier]

Bulletin of the Atomic Scientists

July 2024

<https://thebulletin.org/magazine/2024-07/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 102(7); 2024 Jul 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/465389/>

[Reviewed earlier]

Cell

Jul 25, 2024 Volume 187 Issue 15 p3787-4128

<https://www.cell.com/cell/current>

[New issue; No digest content identified]

Child Care, Health and Development

Volume 50, Issue 5 September 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[New issue; No digest content identified]

Clinical Pharmacology & Therapeutics

Volume 116, Issue 2 Pages: 257-477 August 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

Issue Focus: Model-Informed Drug Development

Clinical Therapeutics

June 2024 Volume 46 Issue 6 p441-516

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 21 Issue 3, June 2024

<https://journals.sagepub.com/toc/ctja/21/3>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 03 Aug 2024]

[No new digest content identified]

Contemporary Clinical Trials

Volume 142 July 2024

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/142/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 7, Issue 3 / June 2024

<https://www.liebertpub.com/toc/crispr/7/3>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 11, Issue 3-4 December 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-3>
[Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 7 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

August 2024 - Volume 37 - Issue 4

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 03 Aug 2024]

[No new digest content identified]

Developing World Bioethics

Volume 24, Issue 2 Pages: 49-134 June 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 34, Issue 4, 2024

<https://www.tandfonline.com/toc/cdip20/34/4>

[Reviewed earlier]

Development Policy Review

Volume 42, Issue 4 July 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 48, Issue 3 July 2024

<https://onlinelibrary.wiley.com/toc/14677717/2024/48/3>

[Reviewed earlier]

EMBO Reports

Volume 25 Issue 7 11 July 2024

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 30, Number 7—July 2024

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 47 June 2024

<https://www.sciencedirect.com/journal/epidemics/vol/47/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 46, Issue 4 Pages: 1-51 July–August 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

Research with refugee populations Ethical considerations for crowdsourced research

[Reviewed earlier]

Ethics & International Affairs

Volume 37 - Issue 4 - Winter 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 34, Issue 3, June 2024

<https://academic.oup.com/eurpub/issue/34/3>

[Reviewed earlier]

Expert Review of Vaccines

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>
[Reviewed earlier]

Foreign Affairs

July/August 2024 Volume 103, Number 4
<https://www.foreignaffairs.com/issues/2023/103/4>
[Reviewed earlier]

Forum for Development Studies

Volume 51, 2024 - Issue 2
<http://www.tandfonline.com/toc/sfds20/current>
[Reviewed earlier]

Genetics in Medicines

Volume 26, Issue 8 August 2024
<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/8>
[New issue; No digest content identified]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>
[Accessed 03 Aug 2024]
[No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024)
<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>
[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 3 June 27, 2024
<http://www.ghspjournal.org/content/current>
[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>
https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc
[Accessed 03 Aug 2024]
[No new digest content identified]

Global Public Health

Volume 19, Issue 1 (2024)
<http://www.tandfonline.com/toc/rqph20/current>
[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 03 Aug 2024]

[No new digest content identified]

Health and Human Rights

Volume 26, Issue 1, June 2024

<https://www.hhrjournal.org/volume-26-issue-1-june-2024/>

SPECIAL SECTION – COMMEMORATING 30 YEARS

[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 2 - April 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 39, Issue 6, July 2024

<https://academic.oup.com/heapol/issue/39/6>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 03 Aug 2024]

[No new digest content identified]

Human Gene Therapy

Volume 35, Issue 13-14 / July 2024

<https://www.liebertpub.com/toc/hum/35/13-14>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 20 Issue 1, 2024

<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>

Selected Content

[Reviewed earlier]

Immunity

Jul 09, 2024 Volume 57 Issue 7 p1443-1712

<https://www.cell.com/immunity/current>

[New issue; No digest content identified]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 03 Aug 2024]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 03 Aug 2024]

Impact of COVID-19 on the neglected tropical diseases: a scoping review

This study investigates the impact of the COVID-19 pandemic on the prevalence, management, and control of the neglected tropical diseases (NTDs) highlighting the current or prospective impact of COVID-19 on re...

Authors: Caitlin Brigid Butala, Roo Nicola Rose Cave, Jenna Fyfe, Paul Gerard Coleman, Guo-Jing Yang and Susan Christina Welburn

Citation: *Infectious Diseases of Poverty* 2024 13:55

Content type: Scoping Review Published on: 29 July 2024

International Health

Volume 16, Issue 4, July 2024

<https://academic.oup.com/inthealth/issue/16/4>

[Reviewed earlier]

International Human Rights Law Review

Volume 13 (2024): Issue 1 (Jun 2024):

<https://brill.com/view/journals/hrlr/13/1/hrlr.13.issue-1.xml>

Special Issue on Inter-State Communications

Table of Contents

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 11 No. 7 (2024): July 2024

<https://www.ijcmph.com/index.php/ijcmph/issue/view/114>

[Reviewed earlier]

International Journal of Epidemiology

Volume 53, Issue 3, June 2024

<https://academic.oup.com/ije/issue/53/3>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 17 Issue 1 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/1>

Table of contents

[Reviewed earlier]

JAMA

July 23/30, 2024, Vol 332, No. 4, Pages 265-346

<https://jamanetwork.com/journals/jama/currentissue>

[Reviewed earlier]

JAMA Health Forum

July 2024, Vol 5, No. 7

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

July 2024, Vol 178, No. 7, Pages 635-732

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JB I Evidence Synthesis

July 2024 - Volume 22 - Issue 7

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[New issue; No digest content identified]

Journal of Adolescent Health

July 2024 Volume 75 Issue 1 p1-206

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 80 (2024)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 49, Issue 3 June 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-3>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[Reviewed earlier]

Journal of Development Economics

Volume 170 September 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/170/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 19 Issue 3, July 2024

<http://journals.sagepub.com/toc/jre/current>

Special Issues in Research and IRB/REC Functioning, Including the use of AI

Research article First published June 17, 2024

[Assessing the Decision-Making Capabilities of Artificial Intelligence Platforms as Institutional Review Board Members](#)

Kannan Sridharan, Gowri Sivaramakrishnan

Research article First published June 17, 2024

[The Ethics of Using Artificial Intelligence in Qualitative Research](#)

David T. Marshall, David B. Naff

Journal of Epidemiology & Community Health

July 2024 - Volume 78 - 7

<https://jech.bmj.com/content/78/7>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 17, Issue 2 Pages: 237-467 June 2024

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 20, Issue 1 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 35, Number 2, May 2024

<https://muse.jhu.edu/issue/52595>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 26, Issue 3 June 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-3>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 22, 2024 _ Issue 3

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 36, Issue 5 Pages: 3-2503 July 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

July 2024 - Volume 50 - 7

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 11, Issue 1 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 270 July 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/270/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024) Issue 1

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

Journal of Public Health Management & Practice

July/August 2024 - Volume 30 - Issue 4

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 45, issue 2, June 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-2>

[Reviewed earlier]

Journal of the Royal Society – Interface

August 2024 Volume 21 Issue 217

<https://royalsocietypublishing.org/toc/rsif/current>

[New issue; No digest content identified]

Journal of Travel Medicine

Volume 31, Issue 5, July 2024

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 98 • Number 6 • June 2024

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Aug 03, 2024 Volume 404 Number 10451 p405-494

<https://www.thelancet.com/journals/lancet/issue/current>

Articles

[Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature](#)

Feixue Wei, Damien Georges, Irene Man, Iacopo Baussano, Gary M Clifford

Understanding the proportion of invasive cervical cancer (ICC) caused by different human papillomavirus (HPV) genotypes can inform primary (ie, vaccination) and secondary (ie, screening) prevention efforts that target specific HPV genotypes. However, using the global literature to estimate population attributable fractions (AFs) requires a methodological framework to address HPV genotype-specific causality from aggregated data. We aimed to estimate the proportion of ICC caused by different HPV genotypes at the global, regional, and national level.

The Lancet Child & Adolescent Health

July 2024 Volume 8 Number 7 p467-544

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Jul 2024 Volume 6 Number 7 e433-e535

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Jul 2024 Volume 12 Number 7 e1068-e1213

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Jul 2024 Volume 24 Number 7 p665-792, e416-e472
<https://www.thelancet.com/journals/laninf/issue/current>
[Reviewed earlier]

Lancet Public Health

Jul 2024 Volume 9 Number 7 e411-e532
<https://www.thelancet.com/journals/lanpub/issue/current>
[Reviewed earlier]

Lancet Respiratory Medicine

Jul 2024 Volume 12 Number 7 p499-574, e42
<https://www.thelancet.com/journals/lanres/issue/current>
[Reviewed earlier]

Maternal and Child Health Journal

Volume 28, Issue 7 July 2024
<https://link.springer.com/journal/10995/volumes-and-issues/28-7>
[Reviewed earlier]

Medical Decision Making (MDM)

Volume 44 Issue 5, July 2024
<http://mdm.sagepub.com/content/current>
[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy
Volume 102, Issue 2 Pages: 271-516 June 2024
<https://onlinelibrary.wiley.com/toc/14680009/current>
[Reviewed earlier]

Molecular Therapy

Jul 03, 2024 Volume 32 Issue 7 p2037-2426
<https://www.cell.com/molecular-therapy/current>
[Reviewed earlier]

Nature

Volume 632 Issue 8023, 1 August 2024
<https://www.nature.com/nature/volumes/632/issues/8022>
Editorial 30 Jul 2024

[Predatory conferences are on the rise. Here are five ways to tackle them](#)

Early-career researchers are being targeted by organizers of exploitative meetings. There needs to be more awareness and perhaps legal redress over this dangerous development.

World View 30 Jul 2024

Guidelines on lab-grown embryo models are strong enough to meet ethical standards — and will build trust in science

The UK code of practice for researchers working with stem-cell-based embryo models is designed to both reassure the public and provide valuable guidance to researchers.

Roger Sturmey

Article Open Access 17 Jul 2024

Sources of gene expression variation in a globally diverse human cohort

A new open-access RNA sequencing dataset, MAGE, of 731 individuals across geographically diverse human populations provides a valuable resource to study genetic diversity and evolution and expands the capacity to identify new genetic associations.

Dylan J. Taylor, Surya B. Chhetri, Rajiv C. McCoy

Nature Biotechnology

Volume 42 Issue 7, July 2024

<https://www.nature.com/nbt/volumes/42/issues/7>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 03 Aug 2024)

[No new digest content identified]

Nature Genetics

Volume 56 Issue 7, July 2024

<https://www.nature.com/ng/volumes/56/issues/7>

[Reviewed earlier]

Nature Human Behaviour

Volume 8 Issue 7, July 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/7>

[Reviewed earlier]

Nature Medicine

Volume 30 Issue 7, July 2024

<https://www.nature.com/nm/volumes/30/issues/7>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 23 Issue 7, July 2024

<https://www.nature.com/nrd/volumes/23/issues/7>

[Reviewed earlier]

Nature Reviews Genetics

Volume 25 Issue 7, July 2024

<https://www.nature.com/nrg/volumes/25/issues/7>

[Reviewed earlier]

Nature Reviews Immunology

Volume 24 Issue 7, July 2024

<https://www.nature.com/nri/volumes/24/issues/7>

[Reviewed earlier]

New England Journal of Medicine

Volume 391 No. 5 August 1, 2024

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

NEJM Evidence

Volume 3 No. 8 August 2024

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[New issue; No digest content identified]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 03 Aug 2024]

[No new digest content identified]

Pediatrics

Volume 154, Issue 1 July 2024

<https://publications.aap.org/pediatrics/issue/154/1>

[Reviewed earlier]

PharmacoEconomics

Volume 42, Issue 7 July 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-7>

[New issue; No digest content identified]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 03 Aug 2024)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 03 Aug 2024)
[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSglobalPublicHealth&q=&resultsPerPage=60

(Accessed 03 Aug 2024)
[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 03 Aug 2024)
[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 03 Aug 2024)
[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 03 Aug 2024]

[Effectiveness of a community-centered Newcastle disease vaccine delivery model under paid and free vaccination frameworks in southeastern Kenya](#)

Kennedy O. Ogolla, Douglas N. Anyona, Judith K. Chemuliti, Winnie W. Kimani, Francisca M. King'oo, Kennedy M. Waweru, Dalmas O. Omia, Isaac K. Nyamongo, Salome A. Bukachi

Research Article | published 01 Aug 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0308088>

[COVID-19 and influenza vaccine-hesitancy subgroups](#)

Karl O. Mäki, Linda C. Karlsson, Johanna K. Kaakinen, Philipp Schmid, Stephan Lewandowsky, Jan Antfolk, Anna Soveri

Research Article | published 30 Jul 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0308159>

[COVID-19 vaccination attitudes and uptake: A sociocultural perspective focusing on parents and peers](#)

Oscar Thompson, Mioara Cristea, Monica Tamariz

Research Article | published 30 Jul 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0300771>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 03 Aug 2024]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

July 30, 2024 vol. 121 no. 31

<https://www.pnas.org/toc/pnas/121/31>

[New issue; No digest content identified]

PNAS Nexus

Volume 3, Issue 6, June 2024

<https://academic.oup.com/pnasnexus/issue/3/6>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 39 - Issue 2 - April 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 184 July 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/184/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

July 2024 Volume 291 Issue 2026

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 232 Pages 1-208 (July 2024)

<https://www.sciencedirect.com/journal/public-health/vol/232/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 17, Issue 1-2, April/July 2024

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2024, Vol. 27, No. 1

<https://karger.com/phg/issue/27/1>

[Reviewed earlier]

Public Health Reports

Volume 139 Issue 4, July/August 2024

<https://journals.sagepub.com/toc/phrg/139/4>

[Reviewed earlier]

Qualitative Health Research

Volume 34 Issue 7, June 2024

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 20 Issue 3, July 2024

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 03 Aug 2024]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest Articles

2 Aug 2024

[From national and regional commitments to global impact: artificial intelligence for equitable public health at the G20](#)

Editorial | English |

Risk Analysis

Volume 44, Issue 7 Pages: 1535-172 July 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

[New issue; No digest content identified]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 03 Aug 2024]

[Reviewed earlier]

Science

Volume 385| Issue 6708| 2 Aug 2024

<https://www.science.org/toc/science/current>

Editorial

[Cell and gene therapy accessibility](#)

BY Rayne H. Rouse, Matthew H. Porteus, 01 Aug 2024

Science and Engineering Ethics

Volume 30, Issue 4 August 2024

<https://link.springer.com/journal/11948/volumes-and-issues/30-4>

Responsibility Gap(s) Due to the Introduction of AI in Healthcare: An Ubuntu-Inspired Approach

Brandon Ferlito, Seppe Segers, Heidi Mertes

Original Research/Scholarship Open access 01 August 2024 Article: 34

Science Translational Medicine

Volume 16| Issue 758| 31 Jul 2024

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 03 Aug 2024]

[No new digest content identified]

Social Science & Medicine

Volume 350 June 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/350/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 03 Aug 2024]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 45, Issue 4 August 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-4>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 60 July–August 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/60/suppl/C>

[New issue; No digest content identified]

Tropical Medicine & International Health

Volume 29, Issue 7 Pages: i-iv, 541-656 July 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 42, Issue 20 13 August 2024

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/20>

Selected Content

Short communication Abstract only

[Uptake among four indicated vaccines by adults aged 65 years and older in Japan, 2023](#)

Masaki Machida, Shinji Fukushima, Akihiko Saitoh, Shigeru Inoue, Takahiro Tabuchi

Article 12598

Research article Abstract only

[Regional differences in provider recommendation of HPV vaccines among 13-to-17 year old adolescents from 2019 to 2021](#)

Chinenye Lynette Ejezie, Paula Cuccaro, Lara S. Savas, Ross Shegog

Article 125974

Research article Open access

[The impact of sub-national heterogeneities in demography and epidemiology on the introduction of rubella vaccination programs in Nigeria](#)

Taishi Nakase, Tenley Brownwright, Oyeladun Okunromade, Abiodun Egwuenu, ... Matthew Ferrari

Article 125982

Research article Open access

[Modelling control strategies for pneumococcal meningitis outbreaks in the African meningitis belt](#)

Liza Hadley, Heidi M. Soeters, Laura V. Cooper, Katya Fernandez, ... Caroline Trotter

Article 125983

Research article Abstract only

[Effectiveness of momentary intervention on influenza vaccination among the elderly in China: From willingness to action](#)

Wan-Xue Zhang, Yuanshan Zhang, Juan Du, Wanna Shi, ... Qing-Bin Lu

Article 125984

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 03 Aug 2024]

Open Access Article

[Addressing Missed Opportunities for Vaccination among Children in Hospitals: Leveraging the P-Process for Health Communication Strategies](#)

by Baldeep K. Dhaliwal, Joseph L. Mathew, Patience N. Obiagwu, Rachel Hill, Chizoba B. Wonodi, Tyler Best and Anita Shet

Vaccines 2024, 12(8), 884; <https://doi.org/10.3390/vaccines12080884> (registering DOI) - 3 Aug 2024

Abstract

Addressing missed opportunities for vaccination requires a nuanced and context-specific approach. The five-step P-Process provides a robust framework to develop a clearly defined strategy that addresses social and behavioral drivers, integrates into existing health delivery systems, and facilitates collaboration with local experts..

Open Access Article

[The Influence of Altitude, Urbanization, and Local Vaccination Centers on Vaccine Uptake within an Italian Health District: An Analysis of 15,000 Individuals Eligible for Vaccination](#)

by Andrea Ceccarelli, Giorgia Soro, Chiara Reali, Emilia Biguzzi, Roberta Farneti, Valeria Frassinetti, Raffaella Angelini, Gian Luigi Belloli, Davide Gori and Marco Montalti
Vaccines 2024, 12(8), 875; <https://doi.org/10.3390/vaccines12080875> - 2 Aug 2024

Abstract

In Italy, free vaccinations for Herpes Zoster (HZ), pneumococcal (PCV), and influenza (FLU) are recommended each year for individuals turning 65. Despite this, achieving optimal vaccination coverage remains challenging. This study assesses coverage rates for HZ, PCV, and FLU in Forlì, Northern Italy,

Open Access Article

[The Impact of Age and Vaccine Conspiracy Beliefs on COVID-19 Vaccine Uptake among United States Adults](#)

by Victoria A. Furlan, Brian N. Chin, Molly Menounos and Dina Anselmi

Vaccines 2024, 12(8), 853; <https://doi.org/10.3390/vaccines12080853> - 30 Jul 2024

Abstract

This observational study examined the relationships between age, vaccine conspiracy beliefs, and COVID-19 vaccine uptake in emerging adults (ages 20–30) and middle-aged adults (ages 50–60) residing in the United States. It also examined sociodemographic predictors of vaccine conspiracy beliefs and COVID-19 vaccine uptake—political

Value in Health

July 2024 Volume 27 Issue 7 p821-998

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Development

Volume 179 July 2024

<https://www.sciencedirect.com/journal/world-development/vol/179/suppl/C>

[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 27 July 2024]

Open Letter metrics AWAITING PEER REVIEW

[An Open Letter on Advancing HIV prevention: Augmenting an ecosystem-based approach to understand prevention decision-making](#)

[version 1; peer review: awaiting peer review]

Nishan Gantayat, James Baer, Alok Gangaramany, Rosemary Pierce-Messick

Peer Reviewers Invited

Funder

Bill and Melinda Gates Foundation

PUBLISHED 02 Aug 2024

In this Open Letter, we focus on demand for HIV prevention to illuminate factors that influence uptake of HIV prevention products and services. These factors exist at three levels of the decision-making ecosystem – the individual level, interaction level and systemic level. We argue that approaching HIV prevention solely through the lens of these levels creates a static view of prevention decision-making. There is a need instead for a dynamic viewpoint that can mirror the changing contexts in which users find themselves and make prevention decisions. We demonstrate that the current ecosystem viewpoint is useful to understand the gaps that exist in program implementation, but does not provide adequate insights into the underlying behaviors that contribute to these gaps. To address this, we suggest an approach to include dynamic aspects of decision-making with factors that influence the individual's assessment of risk, their evaluation of the opportunities to use HIV prevention, and their effective use of prevention products.

Study Protocol metrics

Revised

Development of a core outcome set for maternal and perinatal health research and surveillance in light of emerging and ongoing epidemic threats

[version 2; peer review: 1 approved, 1 approved with reservations]

Veronica Pingray, Karen Klein, Juan Pedro Alonso, María Belizan, Gabriella Radice, Magdalena Babinska, Mabel Berrueta, Mercedes Bonet

Peer Reviewers Ushma Mehta; Kumanan Wilson

Funders

Bill and Melinda Gates Foundation

World Health Organization

LATEST VERSION PUBLISHED 01 Aug 2024

Maternal and perinatal health is often directly and indirectly affected during infectious disease epidemics. Yet, a lack of evidence on epidemics' impact on women and their offspring delays informed decision-making for healthcare providers, pregnant women, women in the post-pregnancy period and policy-makers. To rapidly generate evidence in these circumstances, we aim to develop a Core Outcome Set (COS) for maternal and perinatal health research and surveillance in light of emerging and ongoing epidemic threats.

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 03 Aug 2024]

[Filter: All articles]

IDENTIFYING PLAUSIBLE RANGES FOR DIFFERENTIAL VACCINE EFFICACY ACROSS HIGH- AND LOW-INCOME SETTINGS: A SYSTEMATIC REVIEW, DESCRIPTIVE META-ANALYSIS, AND ILLUSTRATIVE EVIDENCE ANALYSIS

Esther Nyadzua Katama, Katherine E. Gallagher, Anoop Shah, D. James Nokes, David A McAllister
medRxiv 2024.07.31.24310913; doi: <https://doi.org/10.1101/2024.07.31.24310913>

Assessing Healthy Vaccinee Bias in COVID-19 Vaccine Effectiveness Studies: A National Cohort Study in Qatar

Hiam Chemaitelly, Houssein H. Ayoub, Peter Coyle, Patrick Tang, Mohammad R. Hasan, Hadi M. Yassine, Asmaa A. Al Thani, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, Anvar Hassan

Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul-Rahim, Gheyath K. Nasrallah, Mohamed Ghaith Al-Kuwari, Hamad Eid Al-Romaihi, Mohamed H. Al-Thani, Abdullatif Al-Khal, Roberto Bertollini, Adeel A. Butt, Laith J. Abu-Raddad
medRxiv 2024.07.28.24311115; doi: <https://doi.org/10.1101/2024.07.28.24311115>

[Unlocking the transformative potential of data science in improving maternal, newborn and child health in Africa: A scoping review protocol](#)

Akuze Joseph, Bancy Ngatia, Samson Yohannes Amare, Phillip Wanduru, Grieven P. Otieno, Rornald Muhumuza Kananura, Fati Kirakoya-Samadoulougou, Agbessi Amouzou, Abiy Seifu Estifanos, Eric O. Ohuma
medRxiv 2024.07.31.24311286; doi: <https://doi.org/10.1101/2024.07.31.24311286>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>
[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-No new digest content identified.]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 27 July 2024]

Selected Research

Case Study Open Access

[OUCRU Outbreak Advisory Board in the COVID-19 Pandemic in Viet Nam](#)

[version 1; peer review: awaiting peer review]

Phan Bao Tran Ngo, Katrina Lawson, Tan Le Van, H Rogier van Doorn, Guy Thwaites

The model of an outbreak advisory board offers an inexpensive, relatively simple way to engage with policy stakeholders, and can be easily replicated by other programs. Despite its limitations, the OAB has contributed to ongoing communication efforts between OUCRU researchers and policy stakeholders in Vietnam. It helped ensure that the organization's research response to the pandemic was relevant, timely, and locally driven and set the foundation for a more comprehensive discussion forum on research and policy related to infectious diseases, namely the OUCRU Infectious Diseases Research and Policy Discussion Forum (OUCRU IDDF).

Research Article Open Access

[The Artificial Intelligence in Public Health Toolkit: A novel resource for stakeholder engagement](#)

[version 1; peer review: awaiting peer review]

Alison J. Wright, et al.

Artificial intelligence (AI) has considerable potential to enhance public health. People using AI systems for public health decisions, or who are affected by such decisions, may need to understand how these systems work, or articulate how much they want decision-makers to trust the system. This public engagement project, part of the Human Behaviour-Change Project, aimed to a) explore people's views regarding trust in, and use of, AI for public health decisions and, based on that, b) create a toolkit of resources to facilitate people critically questioning the use of an AI system.

*

*

*

*

Think Tanks

Brookings [to 03 Aug 2024]
<http://www.brookings.edu/Research>
No new digest content identified.

Center for Global Development [to 03 Aug 2024]
<https://www.cgdev.org/>
All Research
No new digest content identified.

Chatham House [to 03 Aug 2024]
<https://www.chathamhouse.org/>
Selected Analysis, Comment, Events
No new digest content identified.

Council on Foreign Relations [to 03 Aug 2024]
<https://www.cfr.org/media/news-releases>
New Releases [Selected]
No new digest content identified.

CSIS [to 03 Aug 2024]
<https://www.csis.org/>
Reports [Selected]
No new digest content identified.

Kaiser Family Foundation [to 03 Aug 2024]
https://www.kff.org/search/?post_type=press-release
Newsroom
No new digest content identified.

McKinsey Global Institute [to 03 Aug 2024]
<https://www.mckinsey.com/mgi/overview>
Latest Research
No new digest content identified.

ODI [Overseas Development Institute] [to 03 Aug 2024]
<https://odi.org/en/publications/>
Publications [Selected]
No new digest content identified.

Pew Research Center [to 03 Aug 2024]
<https://www.pewresearch.org/>
Latest Publications [Selected]
No new digest content identified.

Rand [to 03 Aug 2024]
<https://www.rand.org/pubs.html>
Published Research [Selected]
No new digest content identified.

Urban Institute [to 03 Aug 2024]
<https://www.urban.org/publications>
New Research Publications - Selected

World Economic Forum [to 03 Aug 2024]
<https://agenda.weforum.org/press/>
Media [Selected]
No new digest content identified.

.....
.....

Public Consultations/Call for Inputs/Call for Papers

Call for Public Comment: General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies that Utilize Real-World Data for Safety Assessment of Medicines.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]

The guideline will focus on non-interventional pharmacoepidemiological studies using Real-World Data (RWD) and will include basic principles that may apply to these studies when real-world data elements are included.

Public consultation dates [announced to date]:

ANVISA, Brazil - Deadline for comments by 24 August 2024
FDA, United States - Deadline for comments by 3 September 2024
MFDS, Republic of Korea - Deadline for comments by 15 July 2024
MHLW/PMDA, Japan - Deadline for comments by 28 July 2024
NMPA, China - Deadline for comments by 12 October 2024
TFDA, Chinese Taipei - Deadline for comments by 30 September 2024

* * * *
* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2024. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*